IL320073A - Method for increasing recombinant protein expression - Google Patents
Method for increasing recombinant protein expressionInfo
- Publication number
- IL320073A IL320073A IL320073A IL32007325A IL320073A IL 320073 A IL320073 A IL 320073A IL 320073 A IL320073 A IL 320073A IL 32007325 A IL32007325 A IL 32007325A IL 320073 A IL320073 A IL 320073A
- Authority
- IL
- Israel
- Prior art keywords
- protein expression
- recombinant protein
- increasing recombinant
- increasing
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22209191 | 2022-11-23 | ||
| PCT/EP2023/082474 WO2024110426A1 (en) | 2022-11-23 | 2023-11-21 | Method for increasing recombinant protein expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320073A true IL320073A (en) | 2025-06-01 |
Family
ID=84535764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320073A IL320073A (en) | 2022-11-23 | 2023-11-21 | Method for increasing recombinant protein expression |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20260098271A1 (en) |
| EP (1) | EP4623086A1 (en) |
| JP (1) | JP2025538565A (en) |
| KR (1) | KR20250110226A (en) |
| CN (1) | CN120225684A (en) |
| AU (1) | AU2023386575A1 (en) |
| IL (1) | IL320073A (en) |
| MX (1) | MX2025005621A (en) |
| TW (1) | TW202430639A (en) |
| WO (1) | WO2024110426A1 (en) |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| ATE159548T1 (en) | 1990-11-13 | 1997-11-15 | Immunex Corp | BIFUNCTIONAL SELECTABLE FUSION GENES |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| IL134653A0 (en) | 1997-08-22 | 2001-04-30 | Roche Diagnostics Gmbh | Zymogenic protease precursors that can be autocatalytically activated and their use |
| PT2857516T (en) | 2000-04-11 | 2017-08-28 | Genentech Inc | Multivalent antibodies and uses therefor |
| DK1399568T3 (en) | 2001-02-01 | 2006-03-27 | Hoffmann La Roche | Process for producing recombinant trypsin |
| EP1856140B1 (en) | 2005-02-17 | 2013-12-25 | Polyphor Ltd. | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity |
| US20080070251A1 (en) | 2006-06-30 | 2008-03-20 | Kaufman Randal J | Method of Producing Factor VIII Proteins by Recombinant Methods |
| US20080044455A1 (en) | 2006-08-21 | 2008-02-21 | Chaim Welczer | Tonsillitus Treatment |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| EP1988101A1 (en) | 2007-05-04 | 2008-11-05 | Novo Nordisk A/S | Improvement of factor VIII polypeptide titers in cell cultures |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| BRPI1014089A2 (en) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | multispecific antibodies comprising full length antibodies and single chain fab fragments |
| PT2417156E (en) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| SG195196A1 (en) | 2011-05-27 | 2013-12-30 | Dutalys | Dual targeting |
| KR101721301B1 (en) | 2011-08-23 | 2017-03-29 | 로슈 글리카트 아게 | Bispecific antigen binding molecules |
| BR112016011027A2 (en) | 2013-12-20 | 2017-12-05 | Genentech Inc | method of producing an antibody, antibodies, pharmaceutical composition, polynucleotide, vector, host cell, method of treating asthma and method of treating a disorder |
| UA117289C2 (en) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | MULTISPECIFIC ANTIBODY |
| EP3174897B1 (en) | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| WO2016118775A1 (en) | 2015-01-21 | 2016-07-28 | Fred Hutchinson Cancer Research Center | Cocal envelope pseudotyped retroviral vector producer cells |
| CA2980189A1 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| WO2018022032A1 (en) | 2016-07-27 | 2018-02-01 | Hewlett-Packard Development Company, L.P. | 3d printing |
| IN201947051091A (en) * | 2017-05-31 | 2019-12-20 | B.R.A.I.N. Biotechnology Research And Information Network Ag | |
| JP6941224B2 (en) | 2018-02-06 | 2021-09-29 | イージス セラピューティクス,エルエルシー | Intranasal epinephrine preparations and methods for the treatment of the disease |
| CN108441516A (en) | 2018-03-27 | 2018-08-24 | 和元生物技术(上海)股份有限公司 | A kind of slow virus CMV-CBh double-promoters transformation vector construction and application |
| MX2020013296A (en) | 2018-06-11 | 2021-05-27 | Oramed Ltd | COMPOSITIONS CONTAINING RECOMBINANT PROTEASE INHIBITOR, METHODS FOR PRODUCING THE SAME AND USES THEREOF. |
| CN110835632B (en) | 2018-08-15 | 2022-01-11 | 华东师范大学 | Use of novel base transition editing system for gene therapy |
| EP3872088A1 (en) | 2020-02-28 | 2021-09-01 | Alganelle | Use of aprotinin as a carrier to produce a recombinant protein, polypeptide or peptide in algae |
| AU2021236391A1 (en) | 2020-03-13 | 2022-09-29 | Capricor, Inc. | Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms |
| CN111607615B (en) | 2020-06-03 | 2022-03-01 | 金河佑本生物制品有限公司 | Preparation method of porcine epidemic diarrhea and porcine transmissible gastroenteritis virus disease bivalent subunit vaccine |
| CN112626121B (en) | 2020-12-29 | 2024-04-09 | 苏州博腾生物制药有限公司 | Antibody expression vector of triple screening mark and application thereof |
-
2023
- 2023-11-21 JP JP2025529923A patent/JP2025538565A/en active Pending
- 2023-11-21 KR KR1020257015864A patent/KR20250110226A/en active Pending
- 2023-11-21 CN CN202380079679.5A patent/CN120225684A/en active Pending
- 2023-11-21 EP EP23809237.3A patent/EP4623086A1/en active Pending
- 2023-11-21 WO PCT/EP2023/082474 patent/WO2024110426A1/en not_active Ceased
- 2023-11-21 AU AU2023386575A patent/AU2023386575A1/en active Pending
- 2023-11-21 IL IL320073A patent/IL320073A/en unknown
- 2023-11-22 TW TW112145088A patent/TW202430639A/en unknown
-
2025
- 2025-05-14 MX MX2025005621A patent/MX2025005621A/en unknown
- 2025-05-20 US US19/213,865 patent/US20260098271A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4623086A1 (en) | 2025-10-01 |
| KR20250110226A (en) | 2025-07-18 |
| AU2023386575A1 (en) | 2025-03-27 |
| TW202430639A (en) | 2024-08-01 |
| JP2025538565A (en) | 2025-11-28 |
| US20260098271A1 (en) | 2026-04-09 |
| CN120225684A (en) | 2025-06-27 |
| WO2024110426A1 (en) | 2024-05-30 |
| MX2025005621A (en) | 2025-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2602231B (en) | Methods for cell-free protein expression | |
| IL304571A (en) | Methods for purification of recombinant proteins | |
| ZA202109714B (en) | Meso-diaminopimelate dehydrogenase variant polypeptide and method for producing l-threonine using same | |
| GB202304982D0 (en) | Protein expression systems | |
| CA3273928A1 (en) | Method for increasing recombinant protein expression | |
| EP4169938A4 (en) | Method for purifying recombinant protein | |
| GB202307936D0 (en) | Fusion protein | |
| GB202307932D0 (en) | Fusion protein | |
| IL319272A (en) | Novel fusion protein specific for cd137 and cd228 | |
| EP3997231A4 (en) | Methods for making recombinant protein | |
| IL310370A (en) | Protein secretion inhibitors | |
| GB202217084D0 (en) | Therapeutic fusion proteins | |
| HK40111955A (en) | Recombinant protein for treating sars-cov2 disease | |
| GB202312969D0 (en) | Modified proteins | |
| GB202301933D0 (en) | Protein | |
| GB202301919D0 (en) | Protein | |
| GB202201714D0 (en) | Protein | |
| GB202201715D0 (en) | Protein | |
| AU2019902468A0 (en) | Methods for making recombinant protein | |
| GB202501869D0 (en) | Method for enhancing self-amplifying RNA mediated protein expression | |
| CA3309005A1 (en) | Tags for enhanced expression of recombinant proteins | |
| GB202416138D0 (en) | Fusion protein | |
| GB202306711D0 (en) | Novel proteins | |
| GB202319601D0 (en) | Polypeptide | |
| IL317593A (en) | Follistatin-fc fusion proteins |